Food Psych Podcast with Christy Harrison · Christy Harrison, MPH, RD, CEDS

[Repost] The Hidden Risks of Weight-Loss Drugs: Behind the GLP-1 Hype with Ragen Chastain

·39 min·2 clips

Chastain says the FDA is approving weight-loss interventions against research the weight-loss industry has spent decades shaping.

Christy Harrison opens by placing the conversation in Food Psych's anti-diet lens. She introduces Regan Chastain as a writer, speaker, and friend of the pod. The focus is GLP-1 drugs used for weight loss. The discussion starts with the downsides and side effects listeners may not be hearing enough about. From there, it turns to how much influence manufacturers have on public discourse. Christy and Regan talk through the ways drug makers shape coverage, partnerships, and the wider conversation around these medications. They point out that media outlets do not often disclose conflicts of interest clearly. One example is coverage that looks like insurance advocacy while quietly making the case for coverage. The conversation points to a New York Times article by Gina Kolata that quoted several experts about why the drugs should be covered by insurance, while those experts had taken money from Novo Nordisk and or Eli Lilly, without that being disclosed. Regan calls insurance coverage the industry's holy grail in the United States. She also connects that push to Medicare and to national formularies in other countries. The episode brings in Novo Nordisk's history around insulin pricing as part of the larger trust question. Regan argues that the company's past decisions matter when people are told to expect price restraint from competition alone. Christy keeps the exchange focused on how weight stigma and weight cycling get folded into the sales pitch. The conversation stays alert to who benefits when those talking points are repeated without much scrutiny. It also keeps coming back to the public appetite for simple answers. The result is a critique that stays specific rather than abstract. It asks listeners to notice where evidence ends and marketing begins. It also leaves room for the fact that people are hearing these drugs praised everywhere. By the end, the episode makes a case for skepticism without losing sight of why the topic feels so urgent.

As heard by us

A grounded look at GLP-1 drugs, media influence, and weight-loss marketing.

This conversation takes on GLP-1 weight-loss drugs from an angle that is often left out: the possible downsides, the side effects, and the role manufacturers play in shaping public discussion.

Read the full review in PlayNext →

Why you'd press play

When you want the GLP-1 debate stripped of hype and traced through side effects, influence, and money.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Food Psych Podcast with Christy Harrison